Abstract
Introduction

Ž .
Nitric oxide NO , a free-radical gas, is now considered an important intracellular messenger in cardiovascular, w x immune, and neural systems 1,2 . This messenger causes various biological actions including vasodilation, inhibition of platelet aggregation, and cytotoxic or cytostatic actions in many kinds of cells. NO is synthesized from L-arginine Ž by three isoenzymes expressed either constitutively neuro-. nal, type I cNOS; endothelial, type III cNOS or following Ž . w x stimulation by cytokines inducible, type II iNOS 2,3 . iNOS generates the sustained release of large amounts of NO in endotoxin-and cytokine-treated neutrophils, hepatocytes, vascular smooth muscle cells and cardiac myocytes. Recent studies showed that iNOS gene expression occurred frequently in failing human cardiac myocytes of ) Ž . Corresponding author. Tel.: q81 285 442111 ext. 3556; fax: q81 Ž . 285 445317; e-mail: uikeda@jichi.ac.jp patients with dilated cardiomyopathy, ischemic heart disw x ease and valvular heart disease 4,5 .
Many inotropic agents, stimulating b-adrenergic recep-Ž . tor or inhibiting phosphodiesterase PDE III, have dramatic short-term beneficial effects in patients with heart failure. However, long-term treatment with these agents results in an unfavorable outcome. Vesnarinone, a quinolinone derivative, is an oral inotropic agent that augments myocardial contractility with little effect on the heart rate w x or myocardial oxygen consumption 6,7 . The mechanisms of action associated with the inotropic properties of vesnarinone in animals include a decrease in the delayed outward w x and inward rectifying potassium currents 8 , an increase in intracellular sodium caused by the prolonged opening of w x sodium channels 9 , and an increase in the inward calcium w x current attributable to the inhibition of PDE III 10,11 . Recently, this agent has also been shown to improve the w x mortality in patients with heart failure 12 . The purpose of ) this study is to determine the effects of vesnarinone on the synthesis of NO, another modulator of cardiac function, in cardiac myocytes.
Methods
Cell culture
Cardiac myocytes were prepared from ventricles of 1-day-old Sprague-Dawley rats as described previously w x 13 . Briefly, after dissociation with 0.25% trypsin, cell suspensions were washed with Dulbecco's Minimum Es-Ž . sential Medium DMEM supplemented with 10% fetal Ž . bovine serum FBS and centrifuged at 500 g for 10 min. The centrifuged cells were then resuspended in 10% FBS containing DMEM. For selective enrichment of cardiac myocytes, the dissociated cells were preplated for 1 h, during which nonmyocytes readily attached to the bottom of the culture dishes. The resulting suspensions of myocytes were plated onto 24-well dishes at a density of 6 Ž . 0.5 = 10 cellsrwell. Thymidine 0.6 mgrml was added during the first 72 h to prevent proliferation of nonmyocytes. Using this method, we routinely obtained enriched cultures containing ) 95% myocytes, as assayed by immuno-fluorescence staining with an anti-myosin heavy w x chain antibody 14 .
The investigation was performed in accordance with the Home Office Guidance on the Operation of the Animals Ž . Scientific Procedure Act, 1986, published by Her Majesty's Stationery Office, London.
Measurement of nitrite leÕels
Cell were incubated in 0.5% FBS containing DMEM, and nitrite in the culture medium was measured by mixing 0.5 ml of the medium with an equal volume of Griess Ž reagent 0.1% naphthylethylenediamine dihydrochloride
. w x and 1% sulfanilamide in 5% phosphoric acid 15 . The absorbance at 550 nm was measured, and nitrite concentration was determined by using a curve calibration from sodium nitrite standards. After washing, the cells were Ž . dissolved in 0.2 ml 1% sodium dodecyl sulfate SDS and Ž used for protein assay BCA protein assay kit; Bio-Rad . assay, Hercules, CA with bovine serum albumin as a standard. Nitrite levels were corrected for protein levels, and data are shown as nmolrmg protein.
Assay for iNOS protein
The expression of iNOS protein was analyzed by immunoblotting with an anti-iNOS antibody as described w x previously 16 . Briefly, cells cultured in 100-mm dishes were lysed in a buffer containing 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM leupeptin, 1 mM pepstatin A, 0.1 mM phenylmethylsulfonyl fluoride and 1 M dithiothreitol, and sonicated. The homogenates were then centrifuged at Ž . 100 000 g for 20 min, and the supernatants 60 mg protein were subjected to 10% SDS-polyacrylamide gel electrophoresis. The separated proteins were electrophoretically transferred onto nitrocellulose membranes, and the resultant blots were incubated with the anti-mouse iNOS antibody for 2 h, followed by peroxidase-labeled antimouse IgG for 1 h. Peroxidase-labeled proteins were de-Ž tected using the ECL detection system Amersham Int., . Bucks, UK on X-ray film.
Reagents
Ž
. Human recombinant interleukin-1b IL-1b , interferon-Ž . g IFN-g and vesnarinone were gifts from Otsuka Phar-Ž . maceuticals Tokushima, Japan . Tumor necrosis factor a Ž . Ž TNFa was purchased from Genzyme Corp. Cambridge, . MA . A monoclonal anti-mouse iNOS antibody, which cross-reacts against rat iNOS, was obtained from Trans-
from Sigma St. Louis, MO . Rp-8-bromoadenosine-3 ,5 -Ž . cyclic monophosphorothioate Rp-8-Br-cAMPS was pur-Ž . chased from Biolog Life Science Institute Bremen, FRG .
Statistical analysis
Data are expressed as means " SEM of four samples, which represented at least three separate experiments. Differences were analyzed by one-way ANOVA combined with Scheffe's test, and values of P -0.05 were considered statistically significant.
Results
Effects of Õesnarinone on nitrite production
Accumulation of nitrite in the medium represents the summation of NOS activity during the time period studied, since NO secreted by cells is rapidly decomposed to the more stable products nitrite and nitrate. As shown in Fig. Ž . Ž . 1, IL-1b 10 ngrml plus TNFa 10 ngrml stimulated the accumulation of nitrite in cardiac myocytes in a timedependent manner. This cytokine-induced nitrite accumulation was significantly increased in the presence of vesnari-Ž . none 100 mM . After a 24 h incubation, the level of cytokine-induced nitrite accumulation in the presence of vesnarinone was about 1.5-2-fold that in the absence of vesnarinone.
As shown in Fig. 2 , incubation with vesnarinone for 24 h increased nitrite production by cytokine-stimulated my-Ž . ocytes dose-dependently 1-100 mM , while vesnarinone by itself did not affect the basal level of nitrite production Ž . data not shown . w x Previously, Hattori et al. 17 reported that vesnarinone inhibited NO synthesis in LPS plus IFN-g-stimulated cardiac myocytes. As shown in Fig. 3 , we thus investigated the effect of vesnarinone on NO synthesis in these cells, and found that vesnarinone also enhanced nitrite production in a dose-dependent manner.
Simultaneous incubation with the NOS inhibitor L-Ž . NMMA 1 mM or the RNA synthesis inhibitor actino-Ž . mycin D 5 mgrml for 24 h completely inhibited vesnari-Ž none-and cytokine-induced nitrite production data not . shown .
Effects of Õesnarinone on iNOS protein expression
We then examined whether or not vesnarinone augmented cytokine-induced NO production at the level of iNOS protein. As shown in Fig. 4 , unstimulated cardiac myocytes expressed no detectable iNOS protein, whereas exposure to cytokines for 24 h clearly induced its expression. Co-incubation with vesnarinone for 24 h further augmented cytokine-induced iNOS protein expression. 
InÕolÕement of cAMP
We also investigated the mechanism of the stimulatory effect of vesnarinone on NO synthesis. It has been reported that vesnarinone increases intracellular cAMP concentraw x tions of ventricular myocytes 11 , and we previously observed that cAMP upregulates iNOS expression in carw x diac myocytes 18 . Thus, we speculated the involvement of a cAMP-dependent pathway in the effect of vesnarinone on NO synthesis. As shown in Fig. 5 , addition of db-cAMP Ž . 1 mM increased the level of nitrite accumulation in IL-1b plus TNFa-treated cells. Addition of vesnarinone to the cultures significantly increased cytokine-induced nitrite accumulation, but its effect was not additive or synergistic in the presence of db-cAMP.
Furthermore, as shown in Fig. 6 , the effect of vesnarinone was significantly inhibited by Rp-8-Br-cAMPS, a competitive inhibitor of protein kinase A, in a dose-dependent manner, while the cytokine-induced nitrite accumulation was not affected by Rp-8-Br-cAMPS.
Discussion
This study was designed to examine whether or not vesnarinone modulates NO production by cytokine-stimulated cardiac myocytes. We measured the accumulation of nitrite, a stable oxidation product of NO, in the medium to indicate the amount of NO synthesis. Vesnarinone alone had no effect on nitrite production; it markedly augmented nitrite production by cytokine-stimulated myocytes in a time-and dose-dependent manner. Its effect was reduced in the presence of L-NMMA or actinomycin D, suggesting that the upregulation of nitrite production by vesnarinone is likely due to the enhanced induction of iNOS. Indeed, Western blot analysis revealed that vesnarinone further increased cytokine-induced iNOS protein levels. w x Previously, Hattori et al. 17 noted that vesnarinone dose-dependently inhibited NO synthesis induced by LPS plus IFN-g in rat cardiac myocytes. A possible reason for the discrepancy between their findings and ours could be that we used the primary culture of neonatal rat cardiac myocytes, while they used the neonatal rat cardiac myocytes at passage 15-20. In our culture system, enriched cultures containing more than 95% cardiac myocytes were w x routinely obtained 14 . However, their cultured myocytes at passage 15-20 probably did not keep the characteristics as cardiac myocytes nor grew without contamination of non-cardiac myocytes. Another possibility is that we used IL-1b plus TNFa-treated myocytes, while they used LPS plus INF-g-treated myocytes. However, we observed that vesnarinone also enhanced nitrite accumulation in our Ž cultured myocytes stimulated with LPS plus INF-g Fig. .
.
Vesnarinone increases intracellular concentrations of cAMP through PDE III inhibition resulting in a positive w x inotropic effect 11 . It has been shown that cAMP enw x hances iNOS mRNA stability in cardiac myocytes 19 and that cAMP-elevating agents, such as forskolin, isoproterenol, and adrenomedullin, augment cytokine-induced NO w x production in cardiac myocytes 18,20 . The causal relationship between the production of cAMP and augmentation of NO synthesis by vesnarinone in rat cardiac myocytes is evidenced by the findings that the cAMP analogue db-cAMP increased cytokine-induced NO production and that the effect of vesnarinone on cytokine-induced NO production was not additive or synergistic in the Ž . presence of db-cAMP Fig. 5 . Furthermore, the effect of Ž . vesnarinone was inhibited by Rp-8-Br-cAMPS Fig. 6 . These findings suggest that vesnarinone augments cytokine-induced NO production, at least partially through a cAMP-dependent pathway.
Previous studies have noted high levels of iNOS activity in endomyocardial biopsy specimens as well as increased plasma levels of nitrite in patients with dilated w x cardiomyopathy 21,22 . High plasma levels of cytokines have also been reported in patients with heart failure w 
Although 60 mg of vesnarinone was shown to improve both the quality of life and the prognosis of patients with heart failure, there was an increase in mortality in the Ž . group of patients treated with high-dose 120 mg vesnariw x none 12 . The therapeutic serum concentrations of vesnarinone in humans are about 13 to 26 mM. In the present study, vesnarinone at more than 30 mM significantly enhanced nitrite accumulation, suggesting that high concentrations of vesnarinone could act as an enhancer of cardiac NO production and deteriorate myocardial contractility and cell viability in heart failure. However, cytoprotective effects of NO on cardiovascular diseases have also been w x shown 33 , and it might be difficult to apply the observed findings in neonatal rat cardiocytes to the adult human heart, and further studies are necessary to determine if the effects of vesnarinone on NO synthesis reported here contribute to the outcome of heart failure.
